TransMedics Group is trading at $81.35, with a -4.34% change and no clear company-specific catalyst identified for the September 11, 2026 decline.
- Fernando Araujo will become CFO effective September 21, 2026.
- The company reaffirmed 2026 revenue guidance of $737 million–$757 million.
- The broader market is higher, so the decline does not appear tied to market-wide risk-off sentiment. Confidence is low pending additional reporting.